Blog

Gilgamesh Pharmaceuticals Successfully Completes Phase 1 SAD/MAD Clinical Trials of GM-1020

Sep 26 • 3 min read

Gilgamesh Pharma, a cutting-edge clinical-stage biotechnology company proudly announces the successful completion of its Phase 1 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) trials for GM-1020, the only novel oral, small-molecule NMDA receptor channel blocker currently in clinical development. This next-generation therapy is poised to potentially transform the treatment landscape for major depression,…

Numinus Wellness Inc. Announces At-The-Market Offering Equity Program

Sep 26 • 4 min read

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), is pleased to announce that it has established an at-the-market equity offering program (the “ATM Program”) that allows the Company to issue and sell up to C$10,000,000 of common shares in the capital of the Company (the “Common Shares”) from time to time, at the Company’s discretion…

Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

Sep 26 • 5 min read

• Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs • At Week 4, 100% of patients in the SSRI cohort responded to SPL026 (DMT) with 92% of patients in remission from depression • No apparent differences in…

Interview with Kernel CEO, Ryan Field

Sep 25 • 1 min read

Psychedelic Invest’s Charley Rose sat down with the CEO of Kernel, Ryan Field. During the interview, Charley does a deep dive into the company’s work building next-generation neuroimaging technology and how it could help advance the field of psychedelic science. Ryan Field offers a fascinating look at how a portable neuroimaging device could be used to propel…

Psychedelic Education is Adapting to Meet the Needs of the Modern Psychedelic Industry

Sep 22 • 7 min read

We are a long way from psychedelic-assisted therapy being taught in American colleges and Universities. However, that doesn’t mean there are no psychedelic education resources for therapists seeking the skillsets needed to work these medicines. Psychedelic education resources are growing rapidly to meet the increase in demand for psychedelic therapy. Programs cover a vast spectrum…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538